Danish pharmaceutical company Novo Nordisk tackles both obesity and diabetes in their current drug pipeline.
Being overweight or obese has long been known to be a risk factor for type 2 diabetes.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
